Watch QNRX. Know when insiders buy.
One email the day a filing lands. Free.
Work order
74
PASS · insiders 88, shorts 60
Insiders, 90 days
+$280K
net buying · 4 buys, 0 sells · cluster
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $553.2MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$18.7MNET CASH —52W 3.25 – 22.30SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q 2026 · Jun 30 | — | — | — | — | −$5.4M | — | — | −$3.1M | — | — | Aug 14 |
| Q 2026 · Mar 31 | — | — | — | — | −$5M | — | — | −$4.9M | — | — | Aug 14 |
| Q 2025 · Dec 31derived | — | — | — | — | −$4.3M | — | — | −$5M | — | — | Mar 26 |
| Q 2025 · Sep 30 | — | — | — | — | −$3.9M | — | — | −$2.2M | — | — | Nov 6 |
| Q 2025 · Jun 30 | — | — | — | — | −$3.7M | — | — | −$3.7M | — | — | Aug 14 |
| Q 2025 · Mar 31 | — | — | — | — | −$3.8M | — | — | −$2.6M | — | — | Aug 14 |
| Q 2024 · Dec 31derived | — | — | — | — | −$2.3M | — | — | −$2.2M | — | — | Mar 26 |
| Q 2024 · Sep 30 | — | — | — | — | −$2.3M | — | — | −$2.2M | — | — | Nov 6 |
| Q 2024 · Jun 30 | — | — | — | — | −$2M | — | — | −$2M | — | — | Nov 6 |
| Q 2024 · Mar 31 | — | — | — | — | −$2.3M | — | — | −$1.4M | — | — | Nov 6 |
| Q 2023 · Dec 31derived | — | — | — | — | −$2M | — | — | −$3.2M | — | — | Mar 13 |
| Q 2023 · Sep 30 | — | — | — | — | −$1.9M | — | — | −$1.3M | — | — | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | — | −$15.8M | — | — | −$13.5M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | — | −$9M | — | — | −$7.9M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | — | −$8.7M | — | — | −$7.9M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | — | −$9.4M | — | — | −$8.5M | — | — | — | — |
| FY2021 · to Dec 31 | $0 | — | — | −$21.5M | — | -0.01 | −$5.7M | — | — | — | — |
| FY2020 · to Dec 31 | $0 | — | — | −$2.1M | — | -0.70 | −$1.3M | — | — | — | — |
Every number comes from Quoin Pharmaceuticals, Ltd.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.